208 related articles for article (PubMed ID: 21561086)
1. Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
Takemura M; Endo S; Matsunaga T; Soda M; Zhao HT; El-Kabbani O; Tajima K; Iinuma M; Hara A
J Nat Prod; 2011 May; 74(5):1201-6. PubMed ID: 21561086
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10.
Soda M; Hu D; Endo S; Takemura M; Li J; Wada R; Ifuku S; Zhao HT; El-Kabbani O; Ohta S; Yamamura K; Toyooka N; Hara A; Matsunaga T
Eur J Med Chem; 2012 Feb; 48():321-9. PubMed ID: 22236472
[TBL] [Abstract][Full Text] [Related]
3. Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening.
Zhao HT; Soda M; Endo S; Hara A; El-Kabbani O
Eur J Med Chem; 2010 Sep; 45(9):4354-7. PubMed ID: 20538382
[TBL] [Abstract][Full Text] [Related]
4. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X
FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137
[TBL] [Abstract][Full Text] [Related]
5. Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids.
Endo S; Matsunaga T; Mamiya H; Ohta C; Soda M; Kitade Y; Tajima K; Zhao HT; El-Kabbani O; Hara A
Arch Biochem Biophys; 2009 Jul; 487(1):1-9. PubMed ID: 19464995
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid.
Endo S; Matsunaga T; Soda M; Tajima K; Zhao HT; El-Kabbani O; Hara A
Biol Pharm Bull; 2010; 33(5):886-90. PubMed ID: 20460771
[TBL] [Abstract][Full Text] [Related]
7. Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxycurcumin: probing the active site of the enzyme with molecular modeling and site-directed mutagenesis.
Matsunaga T; Endo S; Soda M; Zhao HT; El-Kabbani O; Tajima K; Hara A
Biochem Biophys Res Commun; 2009 Nov; 389(1):128-32. PubMed ID: 19706287
[TBL] [Abstract][Full Text] [Related]
8. Involvement of the aldo-keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms.
Matsunaga T; Yamane Y; Iida K; Endo S; Banno Y; El-Kabbani O; Hara A
Anticancer Drugs; 2011 Jun; 22(5):402-8. PubMed ID: 21317765
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of aldo-keto reductase family 1 member B10 by unsaturated fatty acids.
Hara A; Endo S; Matsunaga T; Soda M; El-Kabbani O; Yashiro K
Arch Biochem Biophys; 2016 Nov; 609():69-76. PubMed ID: 27665999
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationship of 2-phenyliminochromene derivatives as inhibitors for aldo-keto reductase (AKR) 1B10.
Endo S; Hu D; Suyama M; Matsunaga T; Sugimoto K; Matsuya Y; El-Kabbani O; Kuwata K; Hara A; Kitade Y; Toyooka N
Bioorg Med Chem; 2013 Nov; 21(21):6378-84. PubMed ID: 24071447
[TBL] [Abstract][Full Text] [Related]
11. Identification of aldo-keto reductase AKR1B10 as a selective target for modification and inhibition by prostaglandin A(1): implications for antitumoral activity.
Díez-Dacal B; Gayarre J; Gharbi S; Timms JF; Coderch C; Gago F; Pérez-Sala D
Cancer Res; 2011 Jun; 71(12):4161-71. PubMed ID: 21507934
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human aldose reductase-like protein (AKR1B10) by α- and γ-mangostins, major components of pericarps of mangosteen.
Soda M; Endo S; Matsunaga T; Zhao HT; El-Kabbani O; Iinuma M; Yamamura K; Hara A
Biol Pharm Bull; 2012; 35(11):2075-80. PubMed ID: 23123477
[TBL] [Abstract][Full Text] [Related]
13. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
Ruiz FX; Cousido-Siah A; Mitschler A; Farrés J; Parés X; Podjarny A
Chem Biol Interact; 2013 Feb; 202(1-3):178-85. PubMed ID: 23295227
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of steroidal derivatives as selective inhibitors of AKR1B10.
Zhang W; Wang L; Zhang L; Chen W; Chen X; Xie M; Yan G; Hu X; Xu J; Zhang J
Steroids; 2014 Aug; 86():39-44. PubMed ID: 24793566
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for the inhibition of AKR1B10 by caffeic acid phenethyl ester (CAPE).
Zhang L; Zhang H; Zheng X; Zhao Y; Chen S; Chen Y; Zhang R; Li Q; Hu X
ChemMedChem; 2014 Apr; 9(4):706-9. PubMed ID: 24436249
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of polyhydroxy steroids as selective inhibitors against AKR1B10 and molecular docking.
Chen W; Chen X; Zhou S; Zhang H; Wang L; Xu J; Hu X; Yin W; Yan G; Zhang J
Steroids; 2016 Jun; 110():1-8. PubMed ID: 26968129
[TBL] [Abstract][Full Text] [Related]
17. Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-γ-dependent mechanism.
Matsunaga T; Suzuki A; Kezuka C; Okumura N; Iguchi K; Inoue I; Soda M; Endo S; El-Kabbani O; Hara A; Ikari A
Chem Biol Interact; 2016 Aug; 256():142-53. PubMed ID: 27417252
[TBL] [Abstract][Full Text] [Related]
18. Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
Zhang W; Li H; Yang Y; Liao J; Yang GY
Cancer Lett; 2014 Dec; 355(2):273-80. PubMed ID: 25304374
[TBL] [Abstract][Full Text] [Related]
19. Murine aldo-keto reductase family 1 subfamily B: identification of AKR1B8 as an ortholog of human AKR1B10.
Joshi A; Rajput S; Wang C; Ma J; Cao D
Biol Chem; 2010 Dec; 391(12):1371-8. PubMed ID: 21087085
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of compound selectivity of aldo-keto reductases using differential scanning fluorimetry.
Kabir A; Endo S; Toyooka N; Fukuoka M; Kuwata K; Kamatari YO
J Biochem; 2017 Feb; 161(2):215-222. PubMed ID: 28003428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
